Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RUXIENCE

(Ruxience)

Phase 1Biologic

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

RUXIENCE is one of 21 biologic programs targeting Hairy Cell Leukemia. It is currently in Phase 1.

1

Indications

2

Total Trials

2

Active Trials

20

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Hairy Cell LeukemiaActive, not recruiting

Hairy Cell LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Hairy Cell Leukemia

#DrugCompanyPhaseTrials

Braftovi

Rituxan

Gazyva

Nipent

Mektovi

Leustatin

Zelboraf

CConrado Roberto Hoffmann Filho

Tylenol

Benadryl

Treanda

AAzurity Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Active, not recruiting

Hairy Cell Leukemia

NCT03805932

Q1 2031

Phase 3Active, not recruiting

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma

NCT05624554

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05624554·300 enrolled

Hairy Cell Leukemia1 trial

A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03805932·18 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 23, 2019

RUXIENCE

BLA BLA761103

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ruxience. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ruxience compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ruxience. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761103). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Related News